Scientific Sessions 2025  /  New Onset HFpEF and “LVH”—Don't Miss the Treatable Zebra: How to Diagnose and Treat Cardiac Amyloidosis in 2025  /  AL Cardiac Amyloidosis: A High Risk, High Reward Condition with Contemporary Treatment
Logo

American Heart Association

  42
  0

Final ID:

AL Cardiac Amyloidosis: A High Risk, High Reward Condition with Contemporary Treatment

  • Maurer, Mathew  ( Columbia University , New York , New York , United States )
  • Witteles, Ronald  ( STANFORD UNIVERSITY SCHOOL OF MED , Stanford , California , United States )
    • Author Disclosures:
    Mathew Maurer: DO have relevant financial relationships ; Advisor:Pfizer:Active (exists now) ; Advisor:Intellia:Active (exists now) ; Advisor:BrigdeBio:Active (exists now) ; Advisor:AstraZeneca:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Alnylam:Active (exists now) | Ronald Witteles: DO have relevant financial relationships ; Advisor:Pfizer:Active (exists now) ; Advisor:Alexion:Past (completed) ; Advisor:BridgeBio:Active (exists now) ; Advisor:Astra Zeneca:Past (completed) ; Advisor:Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

New Onset HFpEF and “LVH”—Don't Miss the Treatable Zebra: How to Diagnose and Treat Cardiac Amyloidosis in 2025

Saturday, 11/08/2025 , 03:15PM - 04:30PM

Cardiovascular Seminar

More abstracts on this topic:
I’m am Worried My Patient May have Cardiac Amyloidosis. A Practical Algorithm to Make the Diagnosis.

Hanna Mazen, Sailer Christine, Kittleson Michelle

Red Flags in New Onset HFpEF that Should Raise Suspicion for Cardiac Amyloidosis

Alexander Kevin, Nativi-nicolau Jose, Raymer David

More abstracts from these authors:
How does the co-occurence of atrial fibrillation and amyloidosis impact management?

Witteles Ronald, Garcia-pavia Pablo

Transforming Treatment in ATTR-CM

Maurer Mathew

You have to be authorized to contact abstract author. Please, Login
Not Available